NEW HORIZON HEALTH LIMITED New Horizon Health Limited Share Price
Equities
6606
KYG6485S1021
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.14 HKD | -19.75% |
|
-.--% | -38.92% |
| 04-08 | New Horizon Health Limited Announces Board Appointments | CI |
| 03-28 | New Horizon Health Limited Announces Delay in Publication Annual Results for the Year Ended December 31, 2023 | CI |
| Sales 2023 * | 1.87B 258M 2.02B 20.63B | Sales 2024 * | 2.9B 400M 3.13B 32.01B | Capitalization | 5.86B 809M 6.33B 64.78B |
|---|---|---|---|---|---|
| Net income 2023 * | 58M 8M 62.66M 641M | Net income 2024 * | 352M 48.58M 380M 3.89B | EV / Sales 2023 * | 2.59 x |
| Net cash position 2023 * | 1.02B 141M 1.1B 11.28B | Net cash position 2024 * | 707M 97.55M 764M 7.81B | EV / Sales 2024 * | 1.78 x |
| P/E ratio 2023 * |
91.5
x | P/E ratio 2024 * |
17
x | Employees | 1,041 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 76.11% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -19.75% | ||
| 3 months | -25.26% | ||
| 6 months | -26.66% | ||
| Current year | -38.92% |
Current year
13.76
23.45
1 year
13.7632.55
3 years
12.7089.65
5 years
12.7089.65
10 years
12.7089.65
| Managers | Title | Age | Since |
|---|---|---|---|
Ye Qing Zhu
CEO | Chief Executive Officer | 52 | 06/06/18 |
Yi You Chen
FOU | Founder | - | 06/06/18 |
Yu Gao
DFI | Director of Finance/CFO | 41 | 31/05/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yi You Chen
FOU | Founder | - | 06/06/18 |
Danke Yu
BRD | Director/Board Member | 54 | 16/02/21 |
Na Xin Yao
BRD | Director/Board Member | 54 | 08/10/20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.12% | 4 M€ | -27.92% | ||
| 0.11% | 2 M€ | -14.14% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.01% | 117 M€ | +1.11% | - |
New Horizon Health Ltd is a China-based investment holding company principally engaged in the research, development, clinical development, test operation and commercialization of screening products for colorectal cancer, gastric cancer and cervical cancer. The Company distributes its ColoClear, Pupu tube and other products to customers through its own network, contracted sales organisations (CSOs) and Internet sales or e-platform operated by healthcare clinics. The Companyâs Youyou Tube (a stool-based self-checking gastric cancer screening test) and CerviClear (a non-invasive urine cervical cancer home screening test) are under development.
Calendar
15/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
13.06
CNY
Average target price
32.48
CNY
Spread / Average Target
+148.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.92% | 811M | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| -50.70% | 3.3B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B | |
| -5.02% | 1.64B |
- Stock Market
- Equities
- 6606 Stock
